Provided by Tiger Fintech (Singapore) Pte. Ltd.

Permian Resources Corp

11.78
+0.16001.38%
Volume:1.25M
Turnover:14.74M
Market Cap:8.25B
PE:8.15
High:11.93
Open:11.90
Low:11.64
Close:11.62
Loading ...

Will Permian Resources (PR) Beat Estimates Again in Its Next Earnings Report?

Zacks
·
22 hours ago

B.R. Goyal Infrastructure Signs Investor Relations Services Agreement with Adfactors PR

MT Newswires Live
·
Yesterday

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

GlobeNewswire
·
16 Apr

Permian Resources Poised for Solid Q1 as Output Seen Topping Consensus, RBC Says

MT Newswires Live
·
15 Apr

PR Times Sees FY Net Y2.12B

Dow Jones
·
11 Apr

This Permian Resources Insider Increased Their Holding By 240% Last Year

Simply Wall St.
·
10 Apr

Westpac’s $50,000 call centre clash lands bank in PR nightmare

The Australian Financial Review
·
10 Apr

Permian Resources put volume heavy and directionally bearish

TIPRANKS
·
08 Apr

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

GlobeNewswire
·
04 Apr

BUZZ-Oil companies slip further, crude prices head lower after China's tariff announcement

Reuters
·
04 Apr

BUZZ-Oil companies slip on lower crude prices

Reuters
·
04 Apr

Permian Resources Is Maintained at Buy by B of A Securities

Dow Jones
·
01 Apr

Permian Resources price target lowered to $17 from $19 at BofA

TIPRANKS
·
01 Apr

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

GlobeNewswire
·
01 Apr

Curis Provides Fourth Quarter 2024 Business Update

PR Newswire
·
31 Mar

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

GlobeNewswire
·
28 Mar

Press Release: Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Dow Jones
·
28 Mar

Permian Resources Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
28 Mar

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

GlobeNewswire
·
26 Mar

Morgan Stanley Adjusts Price Target on Permian Resources to $19 From $21, Keeps Overweight Rating

MT Newswires Live
·
26 Mar